Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 6/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.51 |
| ▸ | GABRP | O00591 | 2/20 | 0.51 |
| ▸ | GABRD | O14764 | 2/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.51 |
| ▸ | GABRE | P78334 | 2/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32691812 | 1.00 | TDO2 (0.51) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| Piperazine SCHEMBL20537341 | 0.92 | TDO2 (0.45) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29832015 | 0.81 | KIF11 (0.55) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL458963 | 0.81 | KIF11 (0.55) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL25298405 | 0.79 | KDM4E (0.55) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL31682284 | 0.79 | KDM4E (0.55) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19651129 | 0.78 | GABRA1 (0.59) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL8128555 | 0.78 | KIF11 (0.61) | TDO2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL251670 | 0.77 | GABRA1 (0.49) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4497738 | 0.76 | GABRP (0.51) | TDO2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2375900-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | Biovista, Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010068867-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| WO-2026063684-A1 | PYRAZINOCARBAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 이화여자대학교 산학협력단 | 2026-03-26 | — | — | WO | disclosed |
| CN-110831943-B | Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-110831943-B | Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-110831943-B | Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-110914270-B | Preparation method of pirlindole enantiomer and salt thereof | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2021255218-A1 | A PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-VIRAL PROTONOPHORE AND A SERINE PROTEASE INHIBITOR | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-12-23 | — | — | WO | disclosed |
| EP-3612534-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2021-12-22 | — | — | EP | disclosed |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| US-5869229-A | HIGH SENSITIVITY IN INFRARED REGION AND A MINIMAL SENSITIVITY CHANGE WITH VARYING STORAGE CONDITIONS | FUJI PHOTO FILM CO., LTD. (JP) | 1999-02-09 | — | — | US | disclosed |
| WO-1998051716-A1 | PROCESS FOR PREPARING TACTIOSELECTIVE POLYOLEFINS IN CONDENSED PHASE USING HAFNOCENES | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998050440-A1 | PROCESS FOR PRODUCING TACTIOSELECTIVE POLYOLEFINS IN CONDENSED PHASE USING TITANOCENES | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998022486-A1 | HETEROCYCLIC METALLOCENES AND POLYMERIZATION CATALYSTS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1998-05-28 | — | — | WO | disclosed |
| EP-0829753-A1 | Photographic silver halide photosensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
| EP-0028270-B1 | PYRAZINO-CARBAZOLES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CASSELLA Aktiengesellschaft (DE) | 1983-02-16 | — | — | EP | disclosed |
| EP-0028270-B1 | PYRAZINO-CARBAZOLES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CASSELLA Aktiengesellschaft (DE) | 1983-02-16 | — | — | EP | disclosed |
| EP-0028270-A1 | Pyrazino-carbazoles, process for their preparation and pharmaceutical compositions containing them | CASSELLA Aktiengesellschaft (DE) | 1981-05-13 | — | — | EP | disclosed |
| US-4258043-A | ANTIDEPRESSANTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | PIR, DRD5, DRD1 | TDO2 1049/4885GABRA1 287/4885GABRG2 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.